# Nature Cancer

Source: https://onco.cc/journals/nature-cancer/  
OnCo record `nature-cancer` (Journal). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nature Cancer is Nature's cancer-specific research journal, launched in 2020, spanning basic biology to translational and clinical cancer studies.

## Summary

Nature Cancer (Nat Cancer) is Nature's cancer-specific research journal, launched in 2020, appearing monthly and published by Springer Nature on a hybrid access model. It spans basic biology to translational and clinical cancer studies, publishing tumour biology, immuno-oncology, computational and AI methods for cancer, and early-phase trial correlative science, with a deliberate remit to cover health-policy and access issues as well. Its readers are cancer researchers across the basic-to-clinical spectrum. Within OnCo it has its own Nature Cancer source feed and is linked from the biographies of Todd Golub and Jakob Nikolas Kather, and it is where a reader would look for computational and AI cancer methods and correlative trial science.

## Fields

- Kind: Journal
- Last checked: 2026-09-09
- Also known as: Nat Cancer; src-nature-cancer
- Publisher: Springer Nature
- Scope: basic cancer biology
- Access: hybrid

## Notes

- Holds: Cancer biology and translational studies across the spectrum. Access: Paywalled.

## Sources

- Nature Portfolio: https://www.nature.com

## Connected records

- collections: [npj Precision Oncology](https://onco.cc/collections/src-npj-precision-oncology/)
- key papers: [A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma](https://onco.cc/key-papers/paper-hayashi-squamous-basal-like-pancreatic-nat-cancer-2020/), [Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity](https://onco.cc/key-papers/paper-ackerman-nat-cancer/), [Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC](https://onco.cc/key-papers/paper-gemstone-302-nat-cancer-2023-update/), [Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression](https://onco.cc/key-papers/paper-antoine-italiano-nat-cancer-2021/)
- people: [Jakob Nikolas Kather](https://onco.cc/people/jakob-nikolas-kather/), [Todd R. Golub](https://onco.cc/people/todd-golub/)

---
JSON: https://onco.cc/api/v1/entities/nature-cancer.json